期刊
NATURE BIOTECHNOLOGY
卷 28, 期 2, 页码 157-159出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.1601
关键词
-
资金
- NIDDK NIH HHS [R01 DK056597, R01 DK056597-07] Funding Source: Medline
Improved affinity for the neonatal Fc receptor (FcRn) is known to extend antibody half-life in vivo. However, this has never been linked with enhanced therapeutic efficacy. We tested whether antibodies with half-lives extended up to fivefold in human (h) FcRn transgenic mice and threefold in cynomolgus monkeys retain efficacy at longer dosing intervals. We observed that prolonged exposure due to FcRn-mediated enhancement of half-life improved antitumor activity of Fc-engineered antibodies in an hFcRn/Rag1(-/-) mouse model. This bridges the demand for dosing convenience with the clinical necessity of maintaining efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据